{
  "abstract": "Background and Importance Atopic dermatitis (AD) is a chronic inflammatory skin disease characterised by eczematous lesions and intense pruritus. Conventional management includes skin care, topical agents, and, in severe cases, systemic therapy or phototherapy. Recent advances have led to the development of biologic and oral targeted therapies acting on specific molecular pathways. In our hospital, available options include the biologics dupilumab, tralokinumab, lebrikizumab, and the Janus kinase (JAK) inhibitors upadacitinib, baricitinib and abrocitinib.Aim and Objectives The study aimed to evaluate the real-world effectiveness of these targeted therapies under pharmaceutical supervision, stratify patients according to the Spanish Society of Hospital Pharmacy’s CMO model, and describes the current therapeutic landscape in our centre.Material and Methods This retrospective observational study was conducted in a secondary-level hospital including 115 patients with moderate-to-severe AD who completed at least 24 weeks of treatment in 2025. Collected variables included demographics, comorbid immune-mediated and Th2-related diseases, treatment line and efficacy outcomes. Effectiveness was measured using EASI (Eczema Area and Severity Index), BSA (Body Surface Area affected), as well as NRS (Numerical Rating Scale) for itch (NRS-P) and sleep disturbance (NRS-S).Results Of 115 patients, 47.8% were female, mean age 40 years; 85.2% were CMO-3. 65.2% were on first-line therapy. Efficacy parameters for the studied drugs were reported as median values with corresponding ranges (minimum–maximum).Abstract 4CPS-270 Table 1 Drug EASI (Baseline) EASI (Follow-up) BSA (Baseline) BSA (Follow-up) NRS-S (Baseline) NRS-S (Follow-up) NRS-P (Baseline) NRS-P (Follow-up) Abrocitinib 21 (16–35) 4.5 (10–35) 12 (10–60) 4.5 (0–80) 7.5 (0–10) 0 (0–10) 8.5 (3–10) 3.5 (0–10) Baricitinib 22 (21–40) 1 (0–18) 16 (5–40) 1 (0–10) 6 (0–1) 0 (0–1) 8 (0–5) 0 (0–5) Dupilumab 24 (10–50) 2 (0–25) 20 (3–90) 1 (0–20) 8 (0–10) 0 (0–6) 8 (0–10) 2 (0–10) Lebrikizumab 22.5 (18–30) 7 (5–35) 19 (10–50) 10.5 (1–40) 7.5 (5–10) 5.5 (0–10) 9 (5–10) 6 (4–10) Tralokinumab 22.5 (16–35) 5.5 (0–35) 25 (10–60) 5 (0–30) 8.5 (0–10) 2 (0–10) 8.5 (3–10) 5 (0–10) Upadacitinib 21 (2–35) 1 (0–28) 13.5 (1–65) 1 (0–50) 8.5 (0–10) 0 (0–9) 10 (3–10) 1 (0–10) Conclusion and Relevance Biologics and JAK inhibitors treatments significantly improved all efficacy parameters, ensuring effective, sustained, and safe disease control, representing the present and future of AD management.Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "Hospital Virgen De La Victoria, Hospital Pharmacy, Málaga, Spain"
      ],
      "name": "S Quirós Alés"
    },
    {
      "affiliations": [
        "Hospital Virgen De La Victoria, Hospital Pharmacy, Málaga, Spain"
      ],
      "name": "AM Cabrera Menacho"
    },
    {
      "affiliations": [
        "Hospital Virgen De La Victoria, Hospital Pharmacy, Málaga, Spain"
      ],
      "name": "C Huelamo Moruno"
    },
    {
      "affiliations": [
        "Hospital Virgen De La Victoria, Hospital Pharmacy, Málaga, Spain"
      ],
      "name": "E Sánchez Yáñez"
    }
  ],
  "title": "4CPS-270 Clinical effectiveness of biologic and JAK inhibitor therapies in moderate-to-severe atopic dermatitis",
  "uid": "cac0ef42-5e49-5139-823c-c7da094af6dc"
}